Marcin L. Pekalski

Oxford, ENG OX12JD, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months.

Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months.

Journal: International journal of molecular sciences
Published: April 30, 2026

Identification of novel type 1 and type 2 diabetes genes by co-localization of human islet eQTL and GWAS variants with colocRedRibbon.

Identification of novel type 1 and type 2 diabetes genes by co-localization of human islet eQTL and GWAS variants with colocRedRibbon.

Journal: Cell genomics
Published: December 12, 2024

CD56bright natural killer cells preferentially kill proliferating CD4+ T cells.

CD56bright natural killer cells preferentially kill proliferating CD4+ T cells.

Journal: Discovery immunology
Published: March 29, 2023

Antigen receptor stimulation induces purifying selection against pathogenic mitochondrial tRNA mutations.

Antigen receptor stimulation induces purifying selection against pathogenic mitochondrial tRNA mutations.

Journal: JCI insight
Published: December 06, 2022

Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes.

Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes.

Journal: Nature communications
Published: April 10, 2022

Thymocyte regulatory variant alters transcription factor binding and protects from type 1 diabetes in infants.

Thymocyte regulatory variant alters transcription factor binding and protects from type 1 diabetes in infants.

Journal: Scientific reports
Published: March 17, 2022

Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol.

Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol.

Journal: BMJ open
Published: November 10, 2021

Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.

Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp620 Risk Allele Drive the Expansion of FOXP3+ Regulatory T Cells and PD-1 Expression.

Journal: Frontiers in immunology
Published: June 20, 2019

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.

Journal: Journal of autoimmunity
Published: July 31, 2018

The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.

The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.

Journal: JCI insight
Published: December 21, 2017

Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.

Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.

Journal: Wellcome open research
Published: August 18, 2017

Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity.

Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity.

Journal: Journal of autoimmunity
Published: May 16, 2017
Showing 1-12 of 32

Last Updated: 09/26/2026